Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer

Prostate

Volumn 63, Issue 1, 2005, Pages 81-90

  Bandyopadhyay, Abhik ^a   Wang, Long ^a   López Casillas, Fernando ^b   Mendoza, Valentín ^b   Yeh, I Tien ^c   Sun, Luzhe ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Angiogenesis; Apoptosis; Betaglycan; Matrix metalloproteinase 9; Prostate cancer; TGF ; Tumor growth

Indexed keywords

ANGIOGENESIS INHIBITOR; COMPLEMENTARY DNA; GELATINASE A; GELATINASE B; HEMOGLOBIN; PLACEBO; SOLUBLE BETA GLYCAN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL MODEL; ARTICLE; BINDING SITE; BOLUS INJECTION; CONTINUOUS INFUSION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; OSMOTIC PUMP; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL DIVISION; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT PROTEINS; SOLUBILITY; TRANSFORMING GROWTH FACTOR BETA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 14944363173     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20166     Document Type: Article

References (36)

1. Denmeade SR, Isaacs JT. Development of prostate cancer treatment: The good news. Prostate 2004;58:211-224.
2. Hegarty NJ, Fitzpatrick JM, Richie JP, Scardino PT, deVere White RW, Schroder FH, Coffey DS. Future prospects in prostate cancer. Prostate 1999;40:261-268.
3. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000;103:295-309.
4. Lyons RM, Moses HL. Transforming growth factors and the regulation of cell proliferation. Eur J Biochem 1990;187:467-473.
5. Russell PJ, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin Chem 1998;44:705-723.
6. Lee C, Sintich SM, Mathews EP, Shah AH, Kundu SD, Perry KT, Cho JS, Ilio KY, Cronauer MV, Janulis L, Sensibar JA. Transforming growth factor-beta in benign and malignant prostate. Prostate 1999;39:285-290.
7. Zentella A, Weis FM, Ralph DA, Laiho M, Massague J. Early gene responses to transforming growth factor-beta in cells lacking growth-suppressive RB function. Mol Cell Biol 1991;11:4952-4958.
8. Murphy CS, Pietenpol JA, Munger K, Howley PM, Moses HL. c-myc and pRB: Role in TGF-beta 1 inhibition of keratinocyte proliferation. Cold Spring Harb Symp Quant Biol 1991;56: 129-135.
9. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Sensibar JA, Kim JH, Kato M, Lee C. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Res 1996; 56:44-48.
10. Williams RH, Stapleton AM, Yang G, Truong LD, Rogers E, Timme TL, Wheeler TM, Scardino PT, Thompson TC. Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: An immunohistochemical study. Clin Cancer Res 1996;2:635-640.
11. Steiner MS, Zhou ZZ, Tonb DC, Barrack ER. Expression of transforming growth factor-beta 1 in prostate cancer. Endocrinology 1994;135:2240-2247.
12. Wikström P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth factor b1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998;37:19-29.
13. Lopez-Casillas F, Payne HM, Andres JL, Massague J. Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: Mapping of ligand binding and GAG attachment sites. J Cell Biol 1994;124:557-568.
14. Pepin MC, Beauchemin M, Plamondon J, O'Connor-McCourt MD. Mapping of the ligand binding domain of the transforming growth factor beta receptor type III by deletion mutagenesis, Proc Natl Acad Sci USA 1994;91:6997-7001.
15. Vilchis-Landeros MM, Montiel L, Mendoza V, Mendoza-Hernandez G, Lopez-Casillas F, Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent. Biochem J 2001;355:215-222.
16. Sun L, Chen C. Expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells. J Biol Chem 1997;272:25367-25372.
17. Bandyopadhyay A, Lopez-Casillas F, Malik SN, Montiel JL, Mendoza V, Yang J, Sun LZ. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res 2002;62:4690-4695.
18. Moren A, Ichijo H, Miyazono K. Molecular cloning and characterization of the human and porcine transforming growth factor-beta type III receptors. Biochem Biophys Res Commun 1992;189:356-362.
19. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995;147:9-19.
20. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86: 353-364.
21. Sehgal I, Thompson TC. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines. Mol Biol Cell 1999;10:407-416.
22. Shimizu S, Nishidawa Y, Kuroda K, Takagi S, Kozaki K, Hyuga S, Saga S, Matsuyama M. Involvement of transforming growth factor beta1 in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells. Cancer Res 1996;56: 3366-3370.
23. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Lang S, Kato M, Oefelein MG, Miyazono K, Nemeth JA, Kozlowski JM, Lee C. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 1996;2:1255-1261.
24. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999;161:182-187.
25. Barrack ER. TGF beta in prostate cancer: A growth inhibitor that can enhance tumorigenicity. Prostate 1997;31:61-70.
26. Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998;78:940-944.
27. Tuxhorn JA, McAlhany SJ, Yang F, Dang TD, Rowley DR. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 2002;62:6021-6025.
28. Drixler TA, Rinkes IH, Ritchie ED, Van Vroonhoven TJ, Gebbink MF, Voest EE. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res 2000;60:1761-1765.
29. van Moorselaar RJ, Voest EE. Angiogenesis in prostate cancer: Its role in disease progression and possible therapeutic approaches. Mol Cell Endocrinol 2002;197:239-250.
30. Lei X, Bandyopadhyay A, Le T, Sun L. Autocrine TGFbeta supports growth and survival of human breast cancer MDA-MB-231 cells. Oncogene 2002;21:7514-7523.
31. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002;109: 1551-1559.
32. Ueki N, Nakazato M, Ohkawa T, Ikeda T, Amuro Y, Hada T, Higashino K. Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: Validity of neutralizing antibodies to block tumor growth. Biochim Biophys Acta 1992;1137:189-196.
33. Weeks BH, He W, Olson KL, Wang XJ. Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis. Cancer Res 2001;61:7435-7443.
34. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000;14:163-176.
35. Samuel SK, Hurta RA, Kondaiah P, Khalil N, Turley EA, Wright JA, Greenberg AH. Autocrine induction of tumor protease production and invasion by a metallothionein-regulated TGF-beta 1 (Ser223, 225). EMBO J 1992;11:1599-1605.
36. Janji B, Melchior C, Gouon V, Vallar L, Kieffer N. Autocrine TGF-beta-regulated expression of adhesion receptors and integrin-linked kinase in HT-144 melanoma cells correlates with their metastatic phenotype. Int J Cancer 1999;83:255-262.